A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Allergan
- 入组人数
- 419
- 主要终点
- Intraocular Pressure (IOP) at Baseline
研究概览
简要总结
A study of Lumigan® 0.01% as administered in standard practice for patients with POAG or OHT. All treatment decisions, care and diagnostic procedures provided are at the discretion of the participating physicians according to their clinical judgment and the local standard of medical care.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of POAG or OHT
- •Prescribed Lumigan® 0.01%
排除标准
- 未提供
研究组 & 干预措施
Lumigan® 0.01%
Lumigan® 0.01% (bimatoprost 0.01% ophthalmic solution) as prescribed by physician per standard practice for up to 14 weeks.
干预措施: bimatoprost 0.01% ophthalmic solution (Drug)
结局指标
主要结局
Intraocular Pressure (IOP) at Baseline
时间窗: Baseline
IOP is a measurement of the fluid pressure inside the eye. IOP was measured in the left and right eyes at Baseline.
IOP at Week 14
时间窗: Week 14
IOP is a measurement of the fluid pressure inside the eye. IOP was measured in the left and right eyes at Week 14.
次要结局
- Physician Evaluation of IOP Lowering in the Study Eye(s)(Week 14)
- Patient Assessment of Tolerability on a 4-Point Scale(Week 14)
- Physician Assessment of Tolerability on a 4-Point Scale(Week 14)
- Percentage of Patients Who Discontinue Lumigan® 0.01% Prior to 14 Weeks of Treatment(14 Weeks)
- Percentage of Patients Who Continue Lumigan® 0.01% Treatment(Week 14)
- Physician Assessment of Patient Compliance Compared to Previous Therapy(Week 14)